MedTrace Logo

High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients

NCT02696590 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-03-02

No results posted yet for this study

Summary

This study aimed to evaluate oral and injectable routes in treatment of hypovitaminosis D in multiple sclerosis (MS) patients. The investigators aimed to assess the efficacy of each method, using the same Mega dose of 600 000 IU D3, in achieving normal serum 25(OH)D level, the durability of the response, the practicality and the possible toxicity.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DIETARY_SUPPLEMENT

Vitamin D3

two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.

Sponsors & Collaborators

  • Isfahan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Masoud Etemadifar, professor · Isfahan MS Society, Isfahan University of Medical Sciences, Isfahan, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
23 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-11-30
Completion
2015-12-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02696590 on ClinicalTrials.gov